Flagship Pioneering and Novo Nordisk have entered into a research collaboration with Metaphore Biotechnologies, Inc. to advance potential treatments for obesity. The collaboration will utilize Metaphore’s MIMIC platform technology to explore and develop up to two multitarget therapeutics focusing on GLP-1R and related biology. This deal marks the third program under the broader strategic framework between Flagship Pioneering and Novo Nordisk aimed at leveraging Flagship’s bioplatform companies for novel cardiometabolic disease solutions. Legal advisory for Flagship was provided by the life sciences team at Goodwin, led by Christopher Denn and supported by a comprehensive team including Ed Amer, Nancy Urizar, Brittany Morreale, David Sackstein, and Frank Qin.

Biotechnology, Pharmaceuticals, Life Sciences,United States, Denmark